Grace Cherry, RN, ​MSN, NP, Melanoma Program, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses ​recent advances in melanoma. 

Significant progress ​has been made in the treatment landscape of melanoma, says Cherry. Moreover, ongoing research suggests that certain combination therapies can re-induce an immune response in patients who progress on PD-1 inhibitors. 

 Moreover, on July 30, 2020, the FDA approved atezolizumab (Tecentriq) in combination with cobimetinib (Cotellic) and vemurafenib (Zelboraf) for patients with 

 V600​–mutation positive advanced melanoma based on findings from the ​phase 3 IMspire150 trial.

This is a valuable addition to the armamentarium, Cherry concludes. 

Videos

Grace Cherry, RN, ​MSN, NP, discusses ​recent advances in melanoma. 

Recent Advances in Melanoma 

Omid Hamid, MD, is a professor of medicine at Cedars-Sinai. He is also director of clinical Research and Immunotherapy and director of Cutaneous Oncology and Melanoma at the The Angeles Clinic and Research Institute, both in Los Angeles, California.

 On Air! I’m your host today, Gina Columbus.

, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

But today, we collaborated with one of our sister brands, Oncology Nursing News (ONN), which delivers news and clinical insights for oncology nursing professionals. We teamed up with ONN Senior Editor Brielle Benyon, and sat down with Omid Hamid, MD, and Grace Cherry, NP. Hamid is chief of research, immune-oncology and co-director of the cutaneous malignancy program at the Angeles Clinic and Research Institute, and Cherry is of UCLA’s Melanoma Program.

In our exclusive interview, Dr. Hamid and Cherry shared the importance of multidisciplinary care for patients with melanoma, how to best manage immunotherapy-related adverse events, and tips for developing trusting relationships with patients so that they feel comfortable reporting toxicities. The key, they both explained, is to establish an open line of patient and provider communication to ensure that toxicities are reported—and handled&mdash;in a timely manner.

Podcasts

Omid Hamid, MD, and Grace Cherry, NP, share the importance of multidisciplinary care for patients with melanoma, how to best manage immunotherapy-related adverse events, and tips for developing trusting relationships with patients so that they feel comfortable reporting toxicities.



Grace Cherry, NP

Articles

Recent Advances in Melanoma

Collaboration Saves Lives: Managing irAEs is a "Dynamic Discussion"